Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma

Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is difficult to cure; non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) DLBCL have worse outcomes than GCB DLBCL. Ibrutinib and lenalidomide are synergistic in vitro in ABC DLBCL and may augment salvage chemotherapy. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Wyndham H., Phillips, Tycel, Popplewell, Leslie, de Vos, Sven, Chhabra, Saurabh, Kimball, Amy S., Beaupre, Darrin, Huang, Da Wei, Wright, George, Kwei, Kevin, Ping, Jerry, Neuenburg, Jutta K., Staudt, Louis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907362/
https://www.ncbi.nlm.nih.gov/pubmed/33856277
http://dx.doi.org/10.1080/10428194.2021.1907371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907362/
https://www.ncbi.nlm.nih.gov/pubmed/33856277
http://dx.doi.org/10.1080/10428194.2021.1907371

Ejemplares similares